<?xml version='1.0' encoding='utf-8'?>
<document id="24161161"><sentence text="Assessment of disease-drug-drug interaction between single-dose tocilizumab and oral contraceptives in women with active rheumatoid arthritis." /><sentence text="The objective of this study was to evaluate the effect of a single intravenous dose of tocilizumab (TCZ) on pharmacokinetics (PK) of oral contraceptive (OC; norethindrone (NE) and ethinyl estradiol (EE)) and on sex hormone levels (progesterone (PG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH)) in subjects with active rheumatoid arthritis (RA) who were on stable doses of methotrexate"><entity charOffset="157-170" id="DDI-PubMed.24161161.s2.e0" text="norethindrone" /><entity charOffset="172-174" id="DDI-PubMed.24161161.s2.e1" text="NE" /><entity charOffset="180-197" id="DDI-PubMed.24161161.s2.e2" text="ethinyl estradiol" /><entity charOffset="231-243" id="DDI-PubMed.24161161.s2.e3" text="progesterone" /><entity charOffset="245-247" id="DDI-PubMed.24161161.s2.e4" text="PG" /><entity charOffset="394-406" id="DDI-PubMed.24161161.s2.e5" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e0" e2="DDI-PubMed.24161161.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e0" e2="DDI-PubMed.24161161.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e0" e2="DDI-PubMed.24161161.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e0" e2="DDI-PubMed.24161161.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e0" e2="DDI-PubMed.24161161.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e0" e2="DDI-PubMed.24161161.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e1" e2="DDI-PubMed.24161161.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e1" e2="DDI-PubMed.24161161.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e1" e2="DDI-PubMed.24161161.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e1" e2="DDI-PubMed.24161161.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e1" e2="DDI-PubMed.24161161.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e2" e2="DDI-PubMed.24161161.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e2" e2="DDI-PubMed.24161161.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e2" e2="DDI-PubMed.24161161.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e2" e2="DDI-PubMed.24161161.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e3" e2="DDI-PubMed.24161161.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e3" e2="DDI-PubMed.24161161.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e3" e2="DDI-PubMed.24161161.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e4" e2="DDI-PubMed.24161161.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24161161.s2.e4" e2="DDI-PubMed.24161161.s2.e5" /></sentence><sentence text="" /><sentence text="This was an open-label, nonrandomized, multicenter, two-parallel group, one-sequence crossover study" /><sentence text=" In Group 1, Cycle 1 was a baseline cycle to determine the PK of OC and levels of sex hormones" /><sentence text=" At the start of Cycle 2, patients continued to receive OC and single TCZ dosing on Day 1" /><sentence text=" In Cycle 2, we determined the PK of OC and levels of sex hormones when OC and TCZ were combined" /><sentence text=" In Cycle 3, we determined the PK of OC and the levels of sex hormones after TCZ treatment was stopped" /><sentence text=" PK for EE and NE were analyzed serially on Day 7 when maximum TCZ effect on inflammation as indicated by C-reactiv protein (CRP) was expected"><entity charOffset="15-26" id="DDI-PubMed.24161161.s9.e0" text="NE" /></sentence><sentence text=" Hormone levels (PG, LH and FSH) were measured mid-cycle (cycle Days 12 - 16 and Day 21) during each cycle"><entity charOffset="17-18" id="DDI-PubMed.24161161.s10.e0" text="PG" /></sentence><sentence text=" Group 2 (healthy subjects) was studied to compare the levels of OC PK exposures with those in each cycle of Group 1 (RA subjects)" /><sentence text="" /><sentence text="Levels of PG, LH and FSH were not affected by the combination of TCZ/OC treatment in RA patients studied"><entity charOffset="10-12" id="DDI-PubMed.24161161.s13.e0" text="PG" /></sentence><sentence text=" No breakthrough bleeding was attributed to the initiation of TCZ treatment in subjects receiving OCs" /><sentence text=" PK exposures of EE and NE were similar between RA and healthy subjects at baseline and were not affected by single-dose TCZ"><entity charOffset="24-25" id="DDI-PubMed.24161161.s15.e0" text="NE" /></sentence><sentence text=" Administration of OC with or without a single dose of TCZ was well tolerated"><entity charOffset="19-21" id="DDI-PubMed.24161161.s16.e0" text="OC" /></sentence><sentence text="" /><sentence text="Data from this study indicated that the PK and sex hormone levels were not affected in RA subjects who had active disease and were on a stable regimen of methotrexate"><entity charOffset="154-166" id="DDI-PubMed.24161161.s18.e0" text="methotrexate" /></sentence><sentence text="" /></document>